8-K: Elevance Health Beats Q3 Estimates, Boosts 2026 Outlook

Elevance Health reported strong third-quarter 2026 results, surpassing expectations and leading to an upward revision of its full-year financial guidance.

Summary

• Elevance Health reported third quarter 2026 operating revenue of $50.4 billion, a 0.7% increase year-over-year.
• Diluted EPS for the quarter was $6.27, with adjusted diluted EPS at $6.99, exceeding expectations.
• The company raised its full-year 2026 diluted EPS guidance to at least $22.00 and adjusted diluted EPS guidance to at least $29.00.
• Full-year 2026 operating cash flow guidance was also increased to at least $6.5 billion.
• The Health Benefits segment saw operating revenue increase by 2.6% to $43.4 billion, while Carelon segment revenue grew 5% to $19.3 billion.
• Medical membership stood at approximately 44.9 million as of September 30, 2026, a decrease of 487,000 year-over-year.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with the company exceeding expectations and raising full-year guidance, indicating strong operational momentum and effective management.

Positives

• Third quarter 2026 results exceeded expectations.
• Full-year 2026 diluted EPS guidance raised to at least $22.00.
• Full-year 2026 adjusted diluted EPS guidance raised to at least $29.00.
• Full-year 2026 operating cash flow guidance raised to at least $6.5 billion.
• Operating revenue increased by 0.7% to $50.4 billion in Q3 2026.
• Carelon segment operating gain increased by 17% year-over-year.
• The company repurchased 0.8 million shares for $330 million in Q3 2026.
• A quarterly dividend of $1.72 per share was declared.

Negatives

• Medical membership decreased by 487,000 year-over-year, primarily in Medicare Advantage, Medicaid, and Employer Group risk-based businesses.
• Health Benefits segment operating gain declined year-over-year due to targeted investments.
• Operating expense ratio increased by 90 basis points year-over-year, reflecting investments.
• Days in Claims Payable increased by 3.5 days year-over-year.

Risks

• Trends in healthcare costs and utilization rates.
• Reduced enrollment in key business segments.
• Ability to secure and implement sufficient premium rates.
• Impact of large-scale medical emergencies or pandemics.
• Changes in federal, state, and international laws and regulations impacting healthcare.
• Risk of cyber-attacks or data security incidents.
• Failure to effectively maintain and modernize information systems.
• Competitive pressures and ability to adapt to industry changes.

Future Outlook

Full-year 2026 diluted EPS guidance has been raised to at least $22.00, and adjusted diluted EPS guidance to at least $29.00. Operating cash flow guidance for the full year 2026 is also raised to at least $6.5 billion. The company anticipates at least 12% growth in adjusted diluted earnings per share in 2027 from a baseline of at least $26.75.

Management Comments

• "Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business."
• "We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75."
• "By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value for our shareholders."

Industry Context

StockSavvy.ai notes that Elevance Health's performance, particularly the increase in operating revenue and raised guidance, aligns with a generally positive trend in the health insurance sector, though membership declines in certain segments highlight ongoing market pressures and competitive dynamics.

Comparison to Industry Standards

• The reported Q3 2026 operating revenue of $50.4 billion represents a 0.7% increase year-over-year, which is a modest growth rate compared to some rapidly expanding tech-focused healthcare disruptors, but indicates stability within a large, established health insurer.
• The adjusted diluted EPS of $6.99 for Q3 2026, and the raised full-year guidance to at least $29.00, suggest performance that is meeting or exceeding industry analyst expectations for large-cap health insurers.
• The benefit expense ratio improvement to 90.6% is a positive indicator, suggesting better cost management relative to claims, which is a key performance metric across the health insurance industry.
• Membership declines in Medicare Advantage and Medicaid segments, while offset by commercial growth, reflect broader industry trends of shifting enrollment patterns and increased competition in government-sponsored programs.

Legal Proceedings

• Potential exposure for certain historical Medicare Advantage risk adjustment data related to a CMS notice dated February 27, 2026, with an accrual of $935 million for the nine months ended September 30, 2026.

Stakeholder Impact

• Shareholders: Positive impact from raised earnings guidance, share repurchases, and declared dividend.
• Consumers/Members: Potential for improved healthcare experience through investments in capabilities, but also facing membership declines in certain government programs.
• Employees: Continued focus on attracting and retaining talent amidst competitive pressures.
• Providers: Ongoing need to contract on cost-effective and competitive terms.

Next Steps

• Continue investing in capabilities to improve member experience, strengthen competitive advantage, and support long-term growth.
• Focus on delivering at least 12% growth in adjusted diluted earnings per share in 2027.
• Manage membership dynamics across different segments (Medicare, Medicaid, Commercial).

Key Dates

Recommendation

The company is performing well, exceeding expectations and raising guidance, which is positive. However, the slight decline in overall medical membership and the significant accrual for Medicare Advantage risk adjustment data warrant a cautious approach. While the core business appears strong, these factors suggest a 'hold' rating until further clarity on the risk adjustment matter and sustained membership growth.

Keywords

Elevance Health, Q3 Earnings, Healthcare, Health Insurance, EPS Guidance, Operating Revenue, Carelon, Medicare Advantage